AKYILDIZ, A. Et Al. 2023. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey. Medicine , vol.102, no.45 .

AKYILDIZ, A., GÜVEN, D. C., Ozluk, A. A., Ismayilov, R., Mutlu, E., Unal, O. U., ... YILDIZ, İ.(2023). The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey. Medicine , vol.102, no.45.

AKYILDIZ, ARİF Et Al. "The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey," Medicine , vol.102, no.45, 2023

AKYILDIZ, ARİF Et Al. "The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey." Medicine , vol.102, no.45, 2023

AKYILDIZ, A. Et Al. (2023) . "The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey." Medicine , vol.102, no.45.

@article{article, author={ARİF AKYILDIZ Et Al. }, title={The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey}, journal={Medicine}, year=2023}